Tetra Radar · FDA Approvals · Decision date
Krystexxa: FDA decision date
Protalix BioTherapeutics, Inc. (PLX) · June 2026
Net sales of Krystexxa reached $1.3B (2025) NASP (nano encapsulated sirolimus plus pegadricase) PDUFA Date – June 2026 Significant unmet needs and challenges.
Source: 8-K of 21 May 2026
The date has passed; Tetra Radar has not recorded an approval.
A PDUFA date is the date by which the FDA has said it will decide on an application. Dates can move, and a decision is not an approval. Tetra Radar observes public information for research purposes. It does not provide investment advice.